| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
— First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome — |
| 02 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.2 Atrium Therapeutics 2 November 2026 RNA L I S T E D www.atriumtherapeutics.com NASDAQ 1 |
| 27 Oct 2026 |
8-K: Other Events
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome |
| 08 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 7, 2026, by and among Atrium Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
— IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in |
| 14 Jul 2026 |
8-K: Other Events
— ATR 1072 is the company’s first precision cardiology program to enter the clinic -- |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, May 14, 2026 / PRNewswire/ – Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium,” “Atrium Therapeutics” or the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the... |
| 27 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Changes in Control of Registrant +1 more
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Such omitted information has been noted in this document with a pla... |
| 26 Feb 2026 |
8-K: Regulation FD Disclosure
This information statement is being furnished to existing stockholders of Avidity Biosciences, Inc. (“Avidity”) in connection with the pro rata distribution (the “Distribution”) by Avidity of all the issued and outstanding shares of comm... |
Loading...